

REMARKS

Applicant wishes to express appreciation for the courtesies extended by Examiner Rao to Applicant's representative, Lars Genieser, during a telephone conversation on March 17, 2010, during which the following was discussed:

- (1) Prior to issuance of the patent, Applicant has amended paragraph [0001] of the specification to revise the statement of government support and to present the priority of which the benefit is claimed. Applicant respectfully requests that this amendment be entered, and that the paragraph as amended appear in the issued patent.
- (2) Applicant respectfully requests that the Examiner initial, sign, and date the following citations on the respective SB/08 forms previously submitted with Information Disclosure Statements (IDSs), indicating that each of these has been considered:
 - Cite Number CA "International Search Report dated October 28, 2005, issued in PCT/US05/05529", previously submitted with the IDS filed August 24, 2010;
 - Cite Number B2 "WO 00/17163 (with English abstract)", previously submitted with the IDS filed November 1, 2007;
 - Cite Number B3 "WO 90/13646 (with English abstract)", previously submitted with the IDS filed November 1, 2007.

Under present USPTO policy, cite numbers CA, B2, and B3 are appropriate for submission in an IDS and consideration by the Examiner. For the convenience of the Examiner, Applicant includes herewith copies of the SB/08 pages listing and the documents referred to by cite numbers CA, B2, and B3. Applicant respectfully requests that the citations CA, B2, and B3 appear on the issued patent.

- (3) In the course of reviewing documents on the U.S. Patent and Trademark Office PAIR system for the above-identified application, Applicant noted a typographical error on an

SB/08 form submitted with the Information Disclosure Statement (IDS) filed November 1, 2007. Applicant submits a replacement page 3 of the SB/08 of the November 1, 2007 IDS correcting citation number C17 (Jones). Applicant respectfully requests that the corrected citation C17 appear on the issued patent. The correction is shown by underlining and strikethrough below:

- [C17, IDS of Nov. 1, 2007] **Jones, Genetics, 85:12 ~~23~~ (1977).**
- (4) Applicant further noted that two documents submitted with IDSs had pages missing. For the citation C136 (Burnstein et al.), listed with the IDS filed October 7, 2009, the corresponding document has pages 178, 180, and 181 missing. For the citation C20 (Balk), listed with the IDS filed November 1, 2007, the corresponding document has page 139 missing. The complete documents for citation C136 (Burnstein et al. Androgen glucocorticoid regulation of androgen receptor cDNA expression. Molecular and Cellular Endocrinology. 1995. v. 115, pp. 177-186) and citation C20 (Balk, Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002. v. 60, pp. 132-139) are enclosed with this paper. Applicant respectfully requests that these two complete documents be associated with the file.

The issue fee for the above-identified application is due on March 22, 2010. Therefore, Applicant would greatly appreciate that the Examiner initial, sign, and date the citation numbers CA, B2, and B3 as indicated in (2) above and the citation number C17 as indicated in (3) above and place the marked SB/08 sheets on the PAIR system.

Applicant understands that no fee is due for this submission. The Commissioner is authorized to charge any deficiency in any patent application processing fees associated with this communication and any other communication filed by this law firm for the above-identified application and to credit any excess payment to Deposit Account No. 22-0261, under Order Number 58086-235854.

Should the Examiner require any additional information or have any questions, Applicant respectfully requests that the Examiner telephone the undersigned at the number indicated below.

Respectfully submitted,



Date: March 18, 2010

Lars H. Genieser, Ph.D.
Registration No. 46,722
VENABLE LLP
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone (Direct): (202) 344-8234
Telephone (Main): (202) 344-4000
Telefax: (202) 344-8300

DC2/1083154